ReviewMolecular & cellular proteomics : MCP2010
Plasma membrane proteomics and its application in clinical cancer biomarker discovery.
Review in Molecular & cellular proteomics : MCP, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 155 citations in OpenAlex.
- Article
- Surfaceome Capture by Multiplex Biotinylation Enables Enhanced Identification of Cell Surface Proteins by Mass Spectrometry.Molecular & cellular proteomics : MCP · 2026Article
- MALDI Matrix: Origins, Innovations, and Frontiers.Chemical reviews · 2026Review
- Proteomic atlas of human peritoneal tissue.Scientific reports · 2026Article
- Surface Proteomic Analysis Reveals the Presence of Noncanonical Cell Membrane Endoplasmic Reticulum Chaperones in High-Grade Gliomas.Journal of proteome research · 2026Article
- Establishing molecular biomarkers for efficient demarcation of tumor and non-tumor tissue in oral squamous cell carcinoma.Scientific reports · 2025Article
- Engineered Proteins and Chemical Tools to Probe the Cell Surface Proteome.Chemical reviews · 2025Review
- Cancer pharmacoinformatics: Databases and analytical tools.Functional & integrative genomics · 2024Review
- Streamlined Biotinylation, Enrichment and Analysis for Enhanced Plasma Membrane Protein Identification Using TurboID and TurboID-Start Biotin Ligases.The Journal of membrane biology · 2024Article
- Microfluidics enabled multi-omics triple-shot mass spectrometry for cell-based therapies.Biomicrofluidics · 2024Article
- Review
- Imaging nanoscale axial dynamics at the basal plasma membrane.The international journal of biochemistry & cell biology · 2023Review
- ELAPOR1 suppresses tumor progression in colorectal cancer and indicates favorable prognosis.Cancer biomarkers : section A of Disease markers · 2023Article
- Genome-wide identification, classification, and characterization of lectin gene superfamily in sweet orange (Citrus sinensis L.).PloS one · 2023Article
- Simple But Efficacious Enrichment of Integral Membrane Proteins and Their Interactions for In-Depth Membrane Proteomics.Molecular & cellular proteomics : MCP · 2022Article
- Integrative genetic and immune cell analysis of plasma proteins in healthy donors identifies novel associations involving primary immune deficiency genes.Genome medicine · 2022Article
- Article
- Emerging roles of protein palmitoylation and its modifying enzymes in cancer cell signal transduction and cancer therapy.International journal of biological sciences · 2022Review
- A label-free optical system with a nanohole array biosensor for discriminating live single cancer cells from normal cells.Nanophotonics (Berlin, Germany) · 2022Article
- Absolute Quantification of Plasma Membrane Receptors Via Quantitative Flow Cytometry.Methods in molecular biology (Clifton, N.J.) · 2022Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plasma membrane proteins that are exposed on the cell surface have important biological functions, such as signaling into and out of the cells, ion transport, and cell-cell and cell-matrix interactions. The expression level of many of the plasma membrane proteins involved in these key functions is altered on cancer cells, and these proteins may also be subject to post-translational modification, such as altered phosphorylation and glycosylation. Additional protein alterations on cancer cells confer metastatic capacities, and some of these cell surface proteins have already been successfully targeted by protein drugs, such as human antibodies, that have enhanced survival of several groups of cancer patients. The combination of novel analytical approaches and subcellular fractionation procedures has made it possible to study the plasma membrane proteome in more detail, which will elucidate cancer biology, particularly metastasis, and guide future development of novel drug targets. The technical advances in plasma membrane proteomics and the consequent biological revelations will be discussed herein. Many of the advances have been made using cancer cell lines, but because the main goal of this research is to improve individualized treatment and increase cancer patient survival, further development is crucial to direct analysis of clinically relevant patient samples. These efforts include optimized specimen handling and preparation as well as improved proteomics platforms. Identification of potentially useful proteomics-based biomarkers must be validated in larger, well defined retrospective and prospective clinical studies, and these combined efforts should result in identification of biomarkers that will greatly improve early detection, prognosis, and prediction of treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.